Background and Purpose-Adipose tissue is considered an endocrine organ that secretes adipokines, which possibly mediate the effects of obesity on the risk of cardiovascular disease. However, there are yet limited prospective data on the association between circulating adipokine levels and the risk of ischemic stroke. We aimed to examine the associations of 3 adipokines (adiponectin, leptin, and resistin) with the risk of ischemic stroke. Methods-We conducted a prospective nested case-control study (972 stroke cases and 972 matched control subjects) within the Women's Health Initiative Observational Study cohort. The control subjects were matched to cases on age, race/ethnicity, date of study enrollment, and follow-up time. Results-Adipokine levels were associated with established stroke risk factors such as obesity and systolic blood pressure.
O besity is associated with increased risk of ischemic stroke. 1 It is hypothesized that adipokines (or adipocytokines), proteins secreted by adipocytes, may be involved in the underlying biological mechanism linking obesity to ischemic stroke due to their potential effects on insulin resistance, 2 systemic inflammation, [3] [4] [5] and endothelial function, 6 -8 which are important pathways involved in atherosclerosis and hence the pathogenesis of cardiovascular disease. 9 Although a few studies have reported an association between circulating adipokine levels and the incidence of coronary heart disease, 10 -12 there are limited prospective data on their association with the risk of ischemic stroke. Furthermore, the existing studies on an adipokine-stroke association are limited by small sample sizes. [13] [14] [15] [16] Therefore, we evaluated the association of baseline circulating levels of adipokines, including adiponectin, leptin, and resistin, with the risk of subsequent development of ischemic stroke in the Hormones and Biomarkers Predicting Stroke (HaBPS) Study, a large nested case-control study of the Women's Health Initiative Observational Study (WHI-OS).
Methods

Study Population
The WHI-OS is an ongoing ethnically and geographically diverse prospective study with long-term follow-up of 93 676 participants at 40 clinical centers in the United States to examine the risk factors for subsequent development of several health outcomes. [17] [18] [19] Briefly, postmenopausal women aged 50 to 79 years were enrolled between 1993 and 1998. At baseline, women were queried about lifestyle factors, medical history, and personal habits. A physical examination was performed to obtain height, weight, and blood pressure. Fasting blood samples were collected, centrifuged, frozen on site at Ϫ70°C, and later shipped to a central specimen repository. As of September 2005, 4.7% of the original 93 676 WHI-OS subjects had been lost to follow-up.
The HaBPS Study
The HaBPS study was a nested case-control study within the WHI-OS that aimed to evaluate if baseline circulating levels of adipokines, novel lipoproteins, inflammatory cytokines, and hemostasis markers were associated with ischemic stroke risk. 20, 21 Women were ineligible if they had a history of myocardial infarction or stroke at baseline.
Medical records were obtained for all potential stroke events that were identified through self-report at annual contacts; adjudication was performed locally by trained physicians who assigned a diagnosis according to standardized criteria. Only stroke events that required hospitalization were considered as potential outcomes and transient ischemic attacks were not included. All locally adjudicated stroke events were then sent for central adjudication by a team of study neurologists. Strokes were classified as ischemic or hemorrhagic on review of reports of brain imaging studies. Ischemic stroke was defined as the rapid onset of a persistent neurological deficit attributed to an obstruction lasting Ͼ24 hours without evidence of other causes unless death supervened or there was a demonstrable lesion compatible with acute stroke on CT tomography or MRI scan. The subtypes of ischemic stroke were classified using Trial of Org 10172 in Acute Stroke Treatment criteria 22 as large artery atherothrombosis, cardioembolic, lacunar (small vessel), or undetermined etiology. Biomarker assays were performed at a later time after all ischemic strokes were adjudicated and classified.
A total of 972 incident ischemic stroke cases were identified from study baseline to July 1, 2003. One control subject was selected from the risk set at the time of the case diagnosis and matched to each case on age at baseline (Ϯ2 years), race/ethnicity, date of study enrollment (Ϯ3 months), and follow-up time.
Laboratory Assays
Using stored plasma samples, the levels of adiponectin and resistin were measured simultaneously by a multiplex assay (Milliplex Human Adipokine Panel A) and those of leptin were measured by Milliplex Human Adipokine Panel B (Millipore, Billerica MA). The interassay coefficients of variation were 11.3%, 11.4%, and 5.3% for adiponectin, resistin, and leptin, respectively. We previously examined the intraclass correlation coefficients of circulating adipokines in a separate study population 23 and reported 3-year intraclass correlation coefficients of 0.82 (95% CI, 0.66, 0.98) for adiponectin, 0.96 (95% CI, 0.91, 0.99) for resistin, and 0.58 (95% CI, 0.25, 0.91) for leptin, indicating that circulating adipokine levels are relatively stable and that a single measurement at baseline may reflect an individual's long-term exposure. Laboratory methods for other biomarkers measured in the HaBPS study such as C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-␣ (TNF-␣), vascular cell adhesion molecule-1 (VCAM-1), high-molecular-weight adiponectin, and hepatocyte growth factor had been reported previously. 20, 24 
Statistical Analysis
Cases and control subjects were first compared with respect to the reported risk factors for ischemic stroke at baseline; because of the matched case-control design, univariable conditional logistic regression and paired t test were used. To assess whether reported risk factors for ischemic stroke at baseline (eg, obesity, smoking, and hypertension) could be potential confounders, we examined their cross-sectional associations with the 3 adipokines among control subjects. Means of the log-transformed adipokines were compared across the categories of each risk factor using analysis of variance. To simplify presentation of data, we report the geometric means of adipokines and their 95% tolerance factors defined as exponential of (1.96ϫSE of the log-transformed adipokine variable), which can readily be manipulated to obtain 95% CIs of the geometric means. Conditional logistic regression model was used for multivariable analyses. The adipokine variables were modeled in quartiles derived from distribution among the control population. The ORs and 95% CIs were estimated using the lowest quartile as the reference category. Tests of linear trend across quartiles were conducted by assigning the median value for each category, fitting this as a continuous variable in the model, and assessing statistical significance using Wald test. The following established stroke risk factors were included in the multivariable model: body mass index (BMI, continuous), waist circumference (continuous), physical activity (metabolic equivalent tests per week in quartiles), current smoking, use of nonsteroidal anti-inflammatory drugs, use of hypertension medication, systolic blood pressure (continuous), diabetes (selfreported treatment or a fasting glucose level Ն126 mg/dL), history of coronary artery disease (none, 1, or Ն2 of the following conditions: angina, congestive heart failure, coronary revascularization procedure, atrial fibrillation, or peripheral artery disease), elevated highdensity lipoprotein cholesterol (Ն50 mg/dL), and triglyceride (continuous). Certain risk factors suggested in the stroke literature (eg, low-density lipoprotein cholesterol level and postmenopausal hormone therapy) were not significantly associated with risk in the present study after adjusting for the aforementioned covariates, and they were not included in the regression model. In an additional regression model, we further adjusted for 2 biomarkers that we previously reported to be associated with ischemic stroke risk in the HaBPS study-hepatocyte growth factor 24 (an angiogenic factor) and CRP 20 -as well as other markers for inflammation and endothelial function (IL-6, TNF-␣, and VCAM-1). Finally, to evaluate if the associations of adipokines with risk of ischemic stroke were modified by other stroke risk factors (eg, BMI, hypertension, and CRP, etc), interaction terms were included and their significance was determined using the Wald test. All statistical analyses were performed using SAS Version 9.1 (SAS Institute, Cary, NC). All statistical tests conducted were 2-sided and probability values Ͻ0.05 were considered statistically significant.
Results
As expected, women who developed ischemic stroke (case patients) had a more adverse cardiovascular disease risk profile-more current smoking, higher BMI, systolic blood pressure and homeostasis model assessment for insulin resistance, lower physical activity and high-density lipoprotein cholesterol, and were likely to have history of diabetes and coronary artery disease-compared with those who remained free of disease (control subjects; Table 1 ). In terms of the adipokines of interest, cases had significantly lower levels of adiponectin and higher levels of leptin and resistin than control subjects. Table 2 shows the relationships of the 3 adipokines with various stroke risk factors at baseline among the control subjects. As expected, all 3 adipokines were associated with adiposity and insulin resistance; BMI, waist circumference, and homeostasis model assessment for insulin resistance were positively associated with the levels of resistin and leptin and inversely with that of adiponectin. Adiponectin and leptin, but not resistin, were associated with sociodemographic factors. Leptin, but not adiponectin or resistin, was inversely associated with postmenopausal hormone use and physical activity. Although leptin and adiponectin were associated with prevalence of hypertension and diabetes, resistin was not associated with these conditions. Finally, the 3 adipokines of interest were associated with circulating lipids and inflamma-tory markers, particularly CRP and IL-6. Both adiponectin and resistin were positively associated with VCAM-1, a marker for endothelial function. Leptin levels increased with those of hepatocyte growth factor, an angiogenic factor that is associated with risk of stroke in this study population. 24 Among the 3 adipokines of interest, leptin correlated moderately with adiponectin (rϭϪ0.30; PϽ0.001) and resistin (rϭ0.14; PϽ0.001), but there was no correlation between adiponectin and resistin levels (rϭϪ0.04; Pϭ0.264). Table 3 shows the association between quartiles of plasma adipokine levels and risk of ischemic stroke. In the model accounting for only the matching factors (age and race/ ethnicity), adiponectin levels were inversely associated with the risk of ischemic stroke (OR comparing Quartile 4 versus Quartile 1, 0.77; 95% CI, 0.59 to 1.01; P trendϭ0.023), whereas levels of leptin (OR, 1.38; 95% CI, 1.05 to 1.80; P trendϭ0.019) and resistin (OR, 1.61; 95% CI, 1.22 to 2.13; P trend Ͻ0.001) were positively associated with this risk. However, when BMI was included in the model, this association remained statistically significant only for resistin (OR comparing Quartile 4 versus Quartile 1, 1.57; 95% CI, 1.18 to 2.08; P trendϭ0.002). Furthermore, this association for resistin remained significant even after additional adjustment for established stroke risk factors (OR between extreme quartiles, 1.39; 95% CI, 1.01 to 1.90; P trendϭ0.036). Further adjustment with additional markers for inflammation (CRP, IL-6, and TNF-␣), angiogenesis (hepatocyte growth factor), and endothelial dysfunction (VCAM-1) also did not attenuate the association between resistin and ischemic stroke (OR for Quartile 4 versus Quartile 1, 1.49; 95% CI, 1.04 to 2.15; P trendϭ0.037). In additional analysis, we also evaluated the association between leptin:adiponectin ratio and ischemic stroke risk; however, the results were null. For the resistinstroke association, we did not observe any effect modification of the resistin-stroke association by risk factors of ischemic stroke (eg, obesity, smoking, postmenopausal hormone use, CRP, etc). The results by subtype of ischemic stroke were similar (data not shown), although the power for this analysis was limited.
Discussion
We found that high circulating resistin, but not adiponectin or leptin, was independently associated with an increased risk of developing ischemic stroke after accounting for obesity and other stroke risk factors. Our study confirms in a large prospective study a positive association between resistin levels and development of ischemic stroke.
A few potential mechanisms may possibly explain the association between resistin and ischemic stroke. Resistin upregulates proinflammatory cytokines such as IL-6 and TNF-␣ in human peripheral blood mononuclear cells through the nuclear factor-B pathway. 3 In addition, it promotes endothelial cell activation, including stimulation of endothelin-1 release and upregulation of cellular adhesion molecules such as VCAM-1 and intercellular adhesion molecule-1. 25 Therefore, resistin may increase the risk of stroke by promoting systemic inflammation and endothelial dysfunction, both of which play a role in atherosclerosis. 9 In a study that conducted a time course of gene expression in the aortas in mice, resistin mRNA levels steadily increased with lesion size. 26 Cross-sectional data in humans have also indicated that high levels of serum resistin are independently associated with carotid intima media thickness, a marker of atherosclerosis. 27 Consistent with its biological activity 28 and findings from previous studies, 29, 30 we found in this study that resistin correlated positively with levels of inflammatory markers (CRP, IL-6, TNF-␣) and VCAM-1, a biomarker for endothelial function. Resistin levels also increased with adiposity in our study, although this was not a consistent observation in other studies. 31, 32 The fact that the association between resistin and ischemic stroke remained significant after we adjusted for obesity as well as markers for inflammation and endothelial dysfunction in multivariable analyses suggests that the effects of resistin on stroke risk cannot be entirely explained by these obesity-associated pathways and may involve additional unidentified biological mechanisms.
Among the 3 adipokines under study, only the effects of resistin on ischemic stroke were independent of obesity. Two factors may explain this observation. As mentioned, other obesity-independent biomechanisms may link resistin with stroke risk. Moreover, unlike adiponectin and leptin that are mainly secreted by adipocytes, other cell types contribute to the circulating levels of resistin, particularly peripheral blood mononuclear cells such as macrophages. 33, 34 Macrophages infiltrating atherosclerotic aneurysms secrete resistin 34 ; hence, resistin may exert its effects on vascular endothelial cells and smooth muscle cells locally in atheromas regardless of adiposity.
Two cross-sectional studies conducted in Japan suggested that serum resistin was significantly higher among those with a history of ischemic stroke compared with control subjects. 35, 36 Other than our study, only 1 other prospective study has evaluated the association between resistin and cardiovascular disease. 16 In this nested case-control study within the European Investigation into Cancer and Nutrition (EPIC)-Postdam Study, resistin was significantly associated with increased risk of myocardial infarction, but not ischemic stroke after adjusting for age, sex, BMI, waist circumference, alcohol intake, education, lipids, hypertension, and diabetes. However, this study was limited by the small number of 97 stroke cases. Nevertheless, in a Greek study among 211 survivors of ischemic stroke, high resistin levels after stroke were associated with increased 5-year morbidity and mortality. 37 Similar to resistin, adiponectin and leptin are associated with inflammation and endothelial dysfunction. 8, 38 Although the relationship between resistin and insulin resistance in humans is unclear, the association of adiponectin and leptin with insulin resistance provides a third mechanism through which these 2 adipokines may contribute to the pathogenesis of cardiovascular disease. 39 Adiponectin has the opposite effects compared with those of resistin and leptin. It suppresses proinflammatory cytokines (eg, TNF and interferon-␥), induces antiinflammatory cytokines (eg, interleukin-10 and interleukin-1 receptor antagonist), improves insulin sensitivity, and stimulates endothelial production of nitric oxide and thereby improves vascular function. 40, 41 In our study, we did observe significant associations of circulating levels of adiponectin and leptin with inflammation markers (eg, CRP and IL-6), homeostasis model assessment for insulin resistance, and various stroke risk factors (eg, hypertension, diabetes, and dyslipidemia). Although leptin and adiponectin may be involved in the pathogenesis of cardiovascular disease due to their bioactivities, our data showed that their associations with ischemic stroke were much attenuated after accounting for obesity and became trivial after further adjustment with other stroke risk factors. This is not surprising given that adiponectin and leptin are synthesized mainly by adipocytes 38 so that their circulating levels are bona fide biomarkers and surrogates for adiposity. Nevertheless, our results indicate that measuring the circulating levels of adiponectin and leptin does not contribute significantly to risk prediction of ische- METs indicates metabolic equivalent tests; Q, quartile; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostasis model assessment for insulin resistance; CRP, C-reactive protein; IL-6, interleukin-6; TNF-␣, tumor necrosis factor-␣; VCAM-1, vascular cell adhesion molecule-1.
*Tolerance factorϭanti-log(1.96ϫSE of log-transformed data). †The total no. of subjects may not add up to 972 control subjects due to missing data. mic stroke beyond the already established clinical risk factors such as obesity and hypertension.
Our finding for adiponectin is consistent with 2 prospective studies that have evaluated this association. 13, 15 Furthermore, we recently reported that a high-molecular-weight fraction of adiponectin, considered to be the more bioavailable form, was also not associated with ischemic stroke risk in this study population. 42 Limited data exist for the leptin-stroke association. In a cross-sectional analysis within National Health And Nutrition Examination Survey (NHANES), circulating leptin levels were significantly associated with ischemic stroke in women, but not among men. 43 However, in a prospective study conducted within the Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Diseases (MONICA) project with 234 cases of ischemic and 42 cases of hemorrhagic stroke, leptin was significantly associated with elevated risk among men but not among women, 15 an observation that is consistent with our results among women.
Our study has a few limitations that warrant discussion. First, we assayed for total levels of resistin and cannot address whether low-molecular-weight resistin is also important in stroke. 44, 45 Second, the relationship of circulating levels of adipokines with those within the target tissue is not clear and requires further investigation. The adjustment for obesity in our multivariable analysis may potentially be "overadjustment"; however, we aimed to evaluate each adipokine as a risk factor for ischemic stroke independent of obesity at the same time as accounting for other obesity effects. In addition, because we evaluated multiple biomarkers in this study, we cannot rule out the possibility of a Type 1 error for the association observed for resistin. Lastly, this study was conducted among postmenopausal women, and our results need to be confirmed in other populations, particularly premenopausal women and men.
In conclusion, our data suggest that circulating levels of resistin, but not those of adiponectin or leptin, are associated with risk of development of ischemic stroke among postmenopausal women, independent of established stroke risk factors. Future epidemiological studies, including studies in men and in premenopausal women, are needed to confirm this finding, and mechanistic studies should further elucidate the role of resistin in the etiopathogenesis and prevention of ischemic stroke.
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